Carlsmed, founded in 2018 and headquartered in San Diego, California, is a pioneering medical technology company focused on revolutionizing spine surgery. Their core mission is to enhance patient outcomes through personalized medicine. Carlsmed's flagship product, the FDA-approved aprevo™ digital-to-device 3D printed implant system, is designed to offer customized solutions for lumbar fusion surgeries. By leveraging patient data and digital technologies, Carlsmed aims to provide healthcare professionals with optimal surgical plans and personalized devices.
Notable affiliated individuals include the founders and key investors who have supported Carlsmed's innovative approach. The company's significant achievement includes the FDA designation of aprevo™ as a breakthrough technology, marking it as the first-ever surgical implant to receive such recognition. Carlsmed's impact is evident in its growing adoption by hospitals and surgeons nationwide, underscoring its role in advancing personalized spine surgery and improving patient care.
